References
- Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128.
- Hilal T, Betcher JA, Leis JF. Economic impact of oral therapies for chronic lymphocytic leukemia-the burden of novelty. Curr Hematol Malig Rep. 2018;13(4):237–243.
- Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22:91–113.
- Goldstein DA, Chen Q, Ayer T, et al. Bevacizumab for metastatic colorectal cancer: a global cost-effectiveness analysis. Oncologist. 2017;22(6):694–699.
- Vogler S, Vitry A, Babar ZU. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39–47.
- van Harten WH, Wind A, de Paoli P, et al. Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 2016;17(1):18–20.
- Gandjour A. Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG. BMC Health Serv Res. 2020;20(1):343.
- Patel KK, Isufi I, Kothari S, et al. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2020;61(14):3387–3394.
- Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
- Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the $50,000-per-qaly threshold. New Eng J Med. 2014;371(9):796–797.
- NICE. National Institute for Health and Care Excellence: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma 2020. [cited 2020]. Available from: https://www.nice.org.uk/guidance/ta649/documents/final-appraisal-determination-document.
- NICE. National Institute for Health and Care Excellence: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (preliminary result) 2020. [cited 2020]. Available from: https://www.nice.org.uk/guidance/GID-TA10463/documents/129.
- Paulden M. Recent amendments to NICE’s value-based assessment of health technologies: implicitly inequitable? Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):239–242.
- Goldstein DA, Chen Q, Ayer T, et al. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol. 2015;1(9):1293–1300.
- De Block M. The difficulty of comparing drug prices between countries. Lancet Oncol. 2016; 17(4):e125.
- Iunes RF, Uribe MV, Torres JB, et al. Confidentiality agreements: a challenge in market regulation. Int J Equity Health. 2019;18(1):11.
- Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res. 2019;19(6):645–661.
- Harkins RA, Patel SP, Flowers CR. Cost-effectiveness of new targeted agents in the treatment of chronic lymphocytic leukemia. Cancer J. 2019;25(6):418–427.
- Fojo T, Lo AW. Price, value, and the cost of cancer drugs. Lancet Oncol. 2016;17(1):3–5.
- Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–2934.
- Hicks LK, Bering H, Carson KR, et al. The ASH choosing wisely(R) campaign: five hematologic tests and treatments to question. Blood. 2013;122(24):3879–3883.